Abbott's PLEX-ID
This article was originally published in The Gray Sheet
Executive Summary
Abbott anticipates a CE-mark approval later this year for its new PLEX-ID system for detecting and characterizing a wide range of pathogens, including infectious agents commonly transmitted in hospitals. The system, the next generation of Abbott's Ibis T5000 Biosensor System, combines PCR amplification with mass spectrometry and will provide results in six to seven hours instead of three or more days, Abbott says
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.